LATAM Cargo is reporting rising pharmaceutical traffic against a global air freight market its own executives describe as flat.

That contrast is the story. One carrier is growing a specialty vertical while the underlying market refuses to. The Loadstar, which reported the remarks, quotes the carrier's assessment of the broader sector in one word: flat.

No growth figure accompanied the claim. That gap matters. A vertical can rise sharply in percentage terms from a small base and still shift little in absolute tonnage. Until LATAM Cargo publishes pharma tonnage or revenue share, the growth claim stays directional, not quantified.

What is actually being claimed?

Two assertions sit in the headline, and they need separating.

The first is carrier-specific. LATAM Cargo says pharmaceutical traffic is increasing. Pharma is a high-yield, handling-intensive commodity. It demands validated cold-chain equipment, temperature-controlled storage and certified handling at each node. Airlines pursue it because yield beats general cargo.

The second is market-wide. The global air freight market is, in the word used, flat. Flat means no volume recovery, no rate momentum and no demand impulse from trade lanes. Carriers cannot rely on a rising tide in that environment. Growth has to be taken from competitors or built vertical by vertical.

Why pharma, and why LATAM's network fits it

Pharmaceutical freight rewards networks with three attributes: short transit times, cold-chain infrastructure and regulatory certification. LATAM Cargo's South American network is heavy in perishables — flowers, salmon, fruit, vaccines' logistical cousins.

Perishables and pharma share a requirement. Both spoil when the cold chain breaks. An airline that already moves temperature-sensitive perishables at scale has handling muscle it can re-point at higher-yielding pharmaceutical cargo.

South America also exports active pharmaceutical ingredients and biological products. If shippers are shifting that traffic from sea to air, or consolidating it with a single carrier, LATAM Cargo benefits without any market growth at all.

That is the likely mechanism behind the claim. What does this change for shippers? A carrier chasing pharma yield will invest in containers, certification and handling — and may offer sharper rates to win validated volume.

The 'flat' market deserves more scrutiny than it gets

The carrier's description of the global market deserves stress-testing. Flat is a claim, not a dataset.

Flat compared with what? A year of post-restocking correction would make modest volumes look stable. Flat against e-commerce-driven peaks would look very different. Airlines measuring on capacity-flown rather than chargeable weight can report stability while yields erode.

The word also does quiet work for the carrier. A flat market flatters LATAM Cargo's pharma growth. If the market offers no tailwind, every point of vertical growth reads as share gain.

That framing is convenient. It is not necessarily wrong. But readers should note what is not said: no tonnage, no yield movement, no lane-level detail, and no comparison with the carrier's other commodity verticals.

The competitive read

n If the global market is flat, capacity discipline decides who profits. Carriers adding freighter capacity into static demand risk yield erosion for everyone. Carriers defending yield instead chase specialty cargo — pharma, perishables, high-value electronics, aerospace parts.

Pharma is the most certification-gated of these. It cannot be won on price alone. That favors incumbent cold-chain operators with validated networks over new entrants discounting general freight.

LATAM Cargo's pharma push fits that logic. It converts existing perishables infrastructure into higher-yield traffic without adding capacity the market cannot absorb.

What would confirm the claim

Verification requires three numbers the statement does not provide.

• Pharma tonnage or tonne-kilometres, by quarter, against the prior year
• Yield per tonne-kilometre for pharma versus general cargo on the same lanes
• Total system volumes, to establish whether growth is share gain or market drift

Absent those, the pharma rise remains a carrier narrative. It is plausible. It is unproven.

The market's flatness is equally testable against published freight indices and airport tonnage reports, which LATAM Cargo did not cite in the remarks reported by The Loadstar.

The forward view

The carrier has staked its growth story on a vertical while conceding the market around it is motionless. That strategy works while pharma demand holds and competitors lack matching cold-chain certification. It strains if pharma rates soften or if the flat market forces rivals to discount into specialty segments. Watch the next quarterly disclosures for tonnage behind the pharma claim — and for any yield figure that shows whether growth is profitable or purchased.